ArticleDigestive diseases and sciences2026
HKDC1 as a Prognostic and Tumor Microenvironment‑Associated Biomarker in Colorectal Cancer: An Integrated Multi‑omics and Spatial Transcriptomic Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gaining Traction: How Adjustable Clip-and-Rubber Band Traction Improves Duodenal Endoscopic Submucosal Dissection.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality, necessitating the discovery of novel metabolic biomarkers. Hexokinases (HKs) are pivotal in dysregulated glucose metabolism. However, the role of HKDC1, which is the fifth and most recently identified isoform, remains poorly understood in CRC.
methodsWe employed an integrated multi-omics approach to characterize HKDC1. Candidate glycolysis-related genes were screened using WGCNA and differential expression analysis across TCGA, GEO, and GTEx datasets. Spatial transcriptomics and single-cell RNA sequencing (scRNA-seq) were utilized to map the precise localization and cellular communication patterns of HKDC1. Findings were validated in a clinical cohort (n = 168) via Western blot and immunohistochemistry. Functional roles were assessed through HKDC1 knockdown in CRC cell lines using CCK-8, colony formation, Transwell, and wound healing assays. Finally, the relationship between HKDC1, immune infiltration, and drug sensitivity was explored.
resultsHKDC1 was significantly upregulated in CRC across multiple cohorts and pan-cancer datasets. Spatial transcriptomics confirmed HKDC1 enrichment specifically within malignant regions compared to benign zones. High HKDC1 expression was identified as an independent prognostic factor correlated with poor overall survival. Functional assays demonstrated that HKDC1 knockdown significantly inhibited CRC cell proliferation, migration, invasion, and was associated with suppression of epithelial-mesenchymal transition (EMT) related features. Mechanistically, scRNA-seq analysis suggested that HKDC1+ epithelial cells may contribute to tumor progression and potentially interact with fibroblasts through ligand-receptor signaling, including the COL1A2-ITGA2 axis. Furthermore, HKDC1 expression was closely associated with immune cell infiltration and predicted drug sensitivity profiles.
conclusionOur study identifies HKDC1 may act as a potential metabolic regulator associated with CRC progression, possibly involving EMT and tumor microenvironmental interactions. HKDC1 may serve as a potential prognostic biomarker and a candidate target for further therapeutic investigation.
Indexed as
Identifiers
42618857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.